The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with ...

Researchers found no significant differences in safety outcomes between trastuzumab biosimilars and the originator product across subgroups. Trastuzumab biosimilars have similar safety profiles as the ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among ...

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need. Trastuzumab deruxtecan, already used in to treat patients with breast, ...

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as ...

A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with ...

TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II ...

The manufacturer recommends an initial trastuzumab dose of 4 mg/kg i.v. over 90 minutes, followed by a weekly maintenance dose of 2 mg/kg i.v. administered over 30 minutes if the initial dose is well ...

Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report Patients with HER2-positive ...

A combination of HER2-targeted drugs used in breast cancer is now available for use in colorectal cancer. This is the first FDA-approved treatment for HER2-positive metastatic colorectal cancer, maker ...